Younger age, less prominent prolapse and concomitant hysterectomies are associated with a higher risk of peri-operative and mesh-related complications after prolapse repair with trocar-guided transvaginal mesh, according to a study presented by a Russian group at the 28th Annual EAU Congress.
[More]
The U.S. Food and Drug Administration today approved Osphena (ospemifene) to treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause.
[More]
Palatin Technologies, Inc. today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).
[More]
Laparoscopic ventral rectoplexy may reduce sexual dysfunction in women with complex posterior floor prolapse, say researchers who found many patients appreciated having postoperative investigation of their symptoms.
[More]
Neurocrine Biosciences, Inc. today announced results from the open-label portion of the six month Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.
[More]
Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of Endometriosis" to the Company's licensor AstraZeneca.
[More]
Palatin Technologies, Inc. today announced the completion of patient dosing and database lock in a double-blind, placebo-controlled, multiple dose, crossover study of bremelanotide, its subcutaneously administered melanocortin agonist for treatment of erectile dysfunction (ED). Palatin expects to report top-line data in the next calendar quarter.
[More]
Shionogi & Co., Ltd. and QuatRx Pharmaceuticals Company, a privately-held pharmaceutical company, today announced that they have entered into a worldwide license agreement to develop and market ospemifene, a selective estrogen receptor modulator ("SERM").
[More]
QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA).
[More]
A surgical procedure known as LUNA (laparoscopic uterosacral nerve ablation) did not result in improvements in chronic pelvic pain, painful menstruation, painful sexual intercourse or quality of life when compared with laparoscopic surgery that does not interrupt pelvic nerve connections, according to a study in the September 2 issue of JAMA.
[More]
The American College of Obstetricians and Gynecologists (ACOG) has warned women against cosmetic procedures advertised as "vaginal rejuvenation," "designer vaginoplasty", "revirgination" and "G-spot amplification".
[More]
Peyronie's disease (PD) is a localized connective tissue disorder that primarily affects the tunica albuginea and the areolar space between the tunica albuginea and erectile tissue.
[More]
The diagnosis and treatment of vulvovaginal pain disorders are progressing through the advancement of intravaginal surface electromyography (SEMG).
[More]
Interventional radiologists at Temple University Hospital now are able to treat many patients with minimally invasive procedures not available only a few years ago. “Conditions that used to require extensive surgery now take an hour or less, and patients leave with a bandaid and walk home,” says Gary Cohen, M.D., Section Chief of Interventional Radiology and Vice Chairman of Radiology. “How can you beat that?”
[More]